MHC Ib-mediated myelin-specific immunosuppression as novel therapeutic approach for multiple sclerosis and MOG antibody diseases

By inducing antigen-specific tolerance with recombinant peptides, the problems of insufficient immune regulation and excessive side effects in existing technologies for multiple sclerosis and MOG antibody diseases are solved, achieving effective inhibition of antigens and safe therapeutic effects.

CN118922435APending Publication Date: 2024-11-08JULIUS MAXIMILIANS UNIV WURZBURG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029746.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-24
Filing Date
2023-03-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing technologies for treating multiple sclerosis (MS) and MOG antibody diseases suffer from insufficient immune regulation or excessive side effects. Furthermore, common drugs cannot effectively cross the blood-brain barrier and cannot exert anti-inflammatory effects in situ, and there is a lack of effective improved drugs.

Method used

Recombinant peptides containing peptide antigens, MHC class Ib molecules (such as HLA-G), and β2-microglobulin are covalently linked to form soluble peptides, which are used to induce antigen-specific tolerance and suppress immune responses.

Benefits of technology

Recombinant peptides can effectively inhibit immune responses against myelin-oligodendrocyte glycoproteins, myelin basic proteins, myelin-associated glycoproteins, or myelin protein lipids, and prevent the formation of MOG-specific autoantibodies, showing better safety and therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005055887690000091
    Figure BDA0005055887690000091
  • Figure BDA0005055887690000101
    Figure BDA0005055887690000101
  • Figure BDA0005055887690000201
    Figure BDA0005055887690000201
Patent Text Reader

Abstract

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also referred to as MHC class Ib molecules) in combination with myelin sheath related peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody diseases, and MOG antibody positive neuromyelitis optica. The present invention more specifically relates to recombinant polypeptides comprising a peptide antigen and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use for the treatment of multiple sclerosis (MS), MOG antibody diseases, and MOG antibody positive neuromyelitis optica.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody-positive neuromyelitis optica. The present invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of non-classical MHC class Ib molecules. The present invention also relates to methods for producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody-positive neuromyelitis optica. Background Art

[0002] Multiple sclerosis (MS) and MOG encephalomyelitis (also known as myelin-oligodendrocyte glycoprotein antibody disease, MOG antibody disease, MOGAD) are autoimmune diseases in which the immune system's T cells attack the myelin sheath of the central nervous system, leading to slowly progressive neurodegeneration. Immunomodulatory therapies can effectively suppress the relapses of disease activity that are characteristic of MS. For the rare MOGAD, which has long been considered a subtype of MS, there are currently no approved treatments, so treatment initially consists of watching and waiting for the disease to progress. In both diseases, slowly progressive neurodegeneration occurs. Some effective treatments for MS, such as the antibodies natalizumab or ocrelizumab or the orally bioavailable S1P inhibitor fingolimod, even carry the risk of persistent and usually harmless JC virus brain infection that can no longer be controlled, leading to progressive multifocal leukoencephalopathy, which is usually fatal. In this regard, the problem of insufficient immunomodulation or excessive immunomodulatory side effects remains unsolved in both diseases, especially with regard to slow progression. Common biologics cannot cross the blood-brain barrier and therefore cannot exert anti-inflammatory effects in situ. In contrast, regulatory cells have been described that can cross the blood-brain barrier well (Schneider-Hohendorf et al., Eur J Immunol. 2010 Dec; 40(12): 3581-90).

[0003] To date, two strategies have been evaluated, at least in early clinical studies. Similar to desensitization strategies in allergies, large amounts of antigens have been administered by different routes to induce antigen-specific tolerance. However, in autoimmune diseases, these strategies have caused severe side effects and have not been successful in the clinic. Attempts to induce tolerance by adoptive transfer of antigen-specific regulatory T cells or antigen-loaded tolerogenic dendritic cells appear more promising. However, these strategies are extremely complex and expensive and require GMP-compliant manufacturing and quality control processes for each patient. Therefore, even if small-scale clinical trials are successful, it remains a big question whether many patients will be able to receive adoptive transfer therapy in the foreseeable future.

[0004] Immunosuppressive MHC class Ib molecules (e.g. HLA-G) are essential for tolerance induction during pregnancy. They exert immunosuppressive effects on various immune cells through immunosuppressive receptors such as ILT2, ILT4 and Kir2DL4. WO2018 / 215340 relates to a combination of MHC class Ib molecules and peptides for targeted therapeutic immunomodulation.

[0005] In general, there remains a need for improved drugs for the treatment of multiple sclerosis (MS) and MOG antibody diseases. Likewise, there is a need for improved drugs for the treatment of MOG antibody-positive neuromyelitis optica (NMO). Summary of the invention

[0006] The inventors have found that human MHC class Ib molecules, such as HLA-G, are capable of inducing antigen-specific tolerance to presented peptide antigens. Therefore, although the structure and sequence of MHC class Ib molecules are similar to those of classical human MHC class Ia molecules that induce antigenic peptide-specific immune responses, according to the present invention, MHC class Ib molecules can be advantageously used to suppress immune responses in an antigen-specific manner. In addition, the inventors have found that molecules other than naturally occurring MHC class Ib molecules, in particular polypeptides that only contain at least one domain of MHC class Ib molecules, preferably at least one α3 domain of MHC class Ib molecules, can be used to suppress immune responses as described in the present invention: the α1 and α2 domains of various Ia molecules can bind to the α3 domain of human MHC class Ib molecules to suppress immune responses to peptides presented by these antigens.

[0007] HLA-G molecules loaded with antigens may be unstable. Therefore, the inventors designed soluble recombinant polypeptides comprising peptide antigens, MHC class Ib molecules (e.g., HLA-G) and β2-microglobulin (b2m), and covalently linked these three components (e.g., via a covalent linker). Alternatively, the antigen-binding α1 and α2 domains of MHC class Ib molecules (e.g., HLA-G) are replaced with corresponding domains of other MHC molecules to enhance the flexibility and versatility of these recombinant polypeptides (e.g., see Figure 2 ). These alternative recombinant polypeptides can be designed together with the antigen binding domains of other human HLA molecules. b The construct of the α1 and α2 domains can present the ovalbumin-derived peptide SIINFEKL to OT-1 T cells. (OT-1 T cells express a transgenic T cell receptor that specifically recognizes this antigen) (WO2018 / 215340).

[0008] Surprisingly, the inventors found that by using the recombinant polypeptide of the present invention, the immune response to human myelin-oligodendrocyte glycoprotein (MOG), human myelin basic protein (MBP), human myelin associated glycoprotein (MAG) or human myelin proteolipid protein (PLP1) can be inhibited. Therefore, according to the present invention, multiple sclerosis (MS), myelin-oligodendrocyte glycoprotein antibody disease (MOG antibody disease) and MOG antibody-positive neuromyelitis optica can be treated by the recombinant polypeptide of the present invention.

[0009] The inventors' experimental data indicate that the presence of a suitable peptide antigen and the α3 domain of an MHC class Ib molecule (e.g., HLA-G) is required to achieve the desired effect. Thus, this approach goes beyond previously described strategies that either use antigenic peptides without co-stimulation (leading to anergic rather than tolerant T cells) or use MHC class Ib molecules in an antigen-nonspecific context.

[0010] Furthermore, according to the present invention, since the recombinant polypeptides of the present invention are expected to exhibit better safety compared to conventional drugs for treating these diseases, which may cause severe side effects (e.g., progressive multifocal leukoencephalopathy), the recombinant polypeptides of the present invention are expected to be highly advantageous in the immunotherapy of multiple sclerosis (MS), MOG antibody disease, and MOG antibody-positive neuromyelitis optica.

[0011] Furthermore, the inventors surprisingly found that the recombinant polypeptides of the present invention not only modulate T cell responses, but also prevent the formation of MOG-specific autoantibodies in model experiments. Since MOG-specific autoantibodies are associated with the pathology of these diseases, this finding is expected to translate into clinical improvement in patients with multiple sclerosis (MS), MOG antibody disease, and MOG antibody-positive neuromyelitis optica.

[0012] Therefore, the present invention relates to the following preferred embodiments:

[0013] 1. A recombinant polypeptide capable of presenting a peptide antigen, the recombinant polypeptide comprising, in order from N-terminus to C-terminus:

[0014] i) a peptide antigen presented by the recombinant polypeptide, wherein the peptide antigen is a peptide of human myelin-oligodendrocyte glycoprotein (MOG), human myelin basic protein (MBP), human myelin associated glycoprotein (MAG), or human myelin proteolipid protein (PLP1);

[0015] ii) optionally, a linker sequence;

[0016] iii) optionally, a human polypeptide domain sequence, said human polypeptide domain sequence comprising a human β2 microglobulin sequence, or

[0017] An amino acid sequence that is at least 90% identical to the amino acid sequence of human β2 microglobulin shown in SEQ ID NO:5;

[0018] iv) optionally, a linker sequence;

[0019] v) optionally, an α1 domain of an MHC molecule;

[0020] vi) optionally, an α2 domain of an MHC molecule;

[0021] vii) an α3 domain of an MHC class Ib molecule or a derivative of the α3 domain of an MHC class Ib molecule, which derivative is capable of binding to ILT2 or ILT4;

[0022] viii) optionally, a protease cleavage site;

[0023] ix) optionally, a spacer sequence; and

[0024] x) Optionally, an affinity tag.

[0025] 2. The recombinant polypeptide according to item 1, wherein the length of the peptide antigen according to i) is 7 to 11 amino acids, preferably 8 to 10 amino acids.

[0026] 3. The recombinant polypeptide according to item 1 or 2, wherein the peptide antigen according to i) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 32 and

[0027] The amino acid sequence of SEQ ID NO:33.

[0028] 4. The recombinant polypeptide according to item 1 or 2, wherein the peptide antigen according to i) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 28 and

[0029] The amino acid sequence of SEQ ID NO:30.

[0030] 5. The recombinant polypeptide according to any of the preceding items, wherein the peptide antigen according to i) is a peptide of human myelin-oligodendrocyte glycoprotein (MOG).

[0031] 6. The recombinant polypeptide according to any one of items 1 to 2 and 4 to 5, wherein the peptide antigen consists of the amino acid sequence of SEQ ID NO: 2.

[0032] 7. The recombinant polypeptide according to any of the preceding items, wherein the α1 domain according to (v) and the α2 domain according to (vi) are derived from human MHC class Ia molecules or from human MHC class Ib molecules.

[0033] 8. The recombinant polypeptide according to item 7, wherein the α1 domain according to (v) and the α2 domain according to (vi) are derived from human MHC class Ia molecules.

[0034] 9. The recombinant polypeptide according to item 8, wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human HLA-A2 molecules.

[0035] 10. The recombinant polypeptide according to item 7, wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human MHC class Ib molecules.

[0036] 11. The recombinant polypeptide according to any of the preceding items, wherein the α3 domain of the MHC class Ib molecule according to (vii) is the α3 domain of human HLA-E, human HLA-F or human HLA-G.

[0037] 12. The recombinant polypeptide according to any preceding item, wherein the α3 domain of the MHC class Ib molecule according to (vii) is the α3 domain of human HLA-G.

[0038] 13. A recombinant polypeptide according to any of the preceding items, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 80% amino acid sequence identity, preferably at least 90% amino acid sequence identity, with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21.

[0039] 14. A recombinant polypeptide according to item 13, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 92% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21.

[0040] 15. A recombinant polypeptide according to item 13, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 94% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21.

[0041] 16. A recombinant polypeptide according to item 13, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 96% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21.

[0042] 17. A recombinant polypeptide according to item 13, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 98% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21.

[0043] 18. A recombinant polypeptide according to item 13, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 99% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21.

[0044] 19. The recombinant polypeptide according to item 13, wherein the α3 domain according to (vii) is the same as the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21.

[0045] 20. A recombinant polypeptide according to any of the preceding items, wherein the linker sequence according to (ii) and / or the linker sequence according to (iv) comprises an amino acid sequence (GGGGS)n, wherein n is an integer equal to or greater than 1.

[0046] 21. The recombinant polypeptide according to item 20, wherein the linker sequence according to (ii) comprises the amino acid sequence (GGGGS)n, wherein n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and is preferably selected from the group consisting of 2, 3, 4 and 5.

[0047] 22. The recombinant polypeptide according to item 20 or 21, wherein the linker sequence according to (iv) comprises the amino acid sequence (GGGGS)n, wherein n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and is preferably selected from the group consisting of 2, 3, 4 and 5.

[0048] 23. A recombinant polypeptide according to any of the preceding items, wherein the sequence of the human polypeptide domain according to (iii) is at least 95% identical to the amino acid sequence of SEQ ID NO:5, preferably at least 98% identical to the amino acid sequence of SEQ ID NO:5, and more preferably identical to the amino acid sequence of SEQ ID NO:5.

[0049] 24. The recombinant polypeptide according to any of the preceding items, wherein the polypeptide is a dimer or a multimer.

[0050] 25. The recombinant polypeptide according to any of the preceding items, wherein the polypeptide comprises or consists of all components i) to vii).

[0051] 26. The recombinant polypeptide according to any of the preceding items, wherein the polypeptide does not comprise components viii) to x).

[0052] 27. The recombinant polypeptide according to any one of items 1 to 25, wherein the polypeptide comprises or consists of all components i) to x).

[0053] 28. The recombinant polypeptide according to any of the preceding items, further comprising an N-terminal secretion signal peptide sequence.

[0054] 29. The recombinant polypeptide according to any one of items 1 to 27, wherein the recombinant polypeptide consists of the following amino acid sequence, which consists of the following ((a) and (b)) in order from N-terminus to C-terminus:

[0055] (a) a peptide antigen selected from the group consisting of the amino acid sequences of SEQ ID NO:2, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33; and

[0056] (b) The amino acid sequence of SEQ ID NO:16.

[0057] 30. The recombinant polypeptide according to any of the preceding items, wherein the recombinant polypeptide is soluble.

[0058] 31. A nucleic acid encoding one or more polypeptides according to any of the preceding items.

[0059] 32. The nucleic acid according to item 31, wherein the nucleic acid is a vector.

[0060] 33. A pharmaceutical composition comprising at least one nucleic acid according to item 31 or 32.

[0061] 34. A pharmaceutical composition or kit comprising at least one recombinant polypeptide according to any one of items 1 to 30.

[0062] 35. The pharmaceutical composition or kit according to item 34, wherein the pharmaceutical composition or kit comprises at least two different recombinant polypeptides according to any one of items 1 to 30, wherein each different polypeptide comprises a different peptide antigen as defined in any one of items 1 to 6.

[0063] 36. Use of the pharmaceutical composition or kit according to any one of items 33 to 35 for treating multiple sclerosis (MS), MOG antibody disease or MOG antibody-positive neuromyelitis optica in a human patient.

[0064] 37. The pharmaceutical composition or kit for use according to item 36, wherein the treatment is the treatment of multiple sclerosis (MS).

[0065] 38. The pharmaceutical composition or kit for use according to item 36, wherein the treatment is treatment of MOG antibody disease.

[0066] 39. The pharmaceutical composition or kit for use according to item 36, wherein the treatment is the treatment of MOG antibody-positive neuromyelitis optica.

[0067] 40. The pharmaceutical composition or kit for use according to any one of items 36 to 39, wherein the treatment is treatment by immunotherapy.

[0068] 41. The pharmaceutical composition or kit for use according to any one of items 36 to 40, wherein the treatment is performed by inducing immune tolerance against human myelin-oligodendrocyte glycoprotein.

[0069] 42. A pharmaceutical composition or kit for use according to any one of items 36 to 41, wherein the treatment is used to reduce the level of autoantibodies against human myelin-oligodendrocyte glycoprotein in plasma or cerebrospinal fluid.

[0070] 43. The pharmaceutical composition or kit for use according to any one of items 36 to 42, wherein the human patient is a patient having anti-myelin-oligodendrocyte glycoprotein autoantibodies in plasma or cerebrospinal fluid before the start of treatment.

[0071] 44. The pharmaceutical composition or kit for use according to any one of items 36 to 43, wherein the treatment is performed by inducing myelin-specific regulatory T cells.

[0072] 45. A recombinant host cell comprising the nucleic acid or vector according to item 31 or 32, and expressing the recombinant polypeptide according to any one of items 1 to 30.

[0073] 46. ​​A method for obtaining a pharmaceutical composition comprising a polypeptide according to any one of items 1 to 30, the method comprising the following steps: (a) culturing the recombinant host cell according to item 45 under conditions that allow expression of the recombinant polypeptide from the nucleic acid molecule,

[0074] (b) recovering the recombinant polypeptide, (c) purifying the recombinant polypeptide, and (d) formulating the recombinant polypeptide into a pharmaceutical composition. BRIEF DESCRIPTION OF THE DRAWINGS

[0075] Figure 1 : Description of peptide-loaded soluble MHC Ib molecules suitable for achieving therapeutic antigen-specific immunomodulation.

[0076] The presented peptide antigen is represented by a dotted sphere, the HLA-Gα-3 domain is represented by a light gray, and the β2 microglobulin domain is represented by a dark gray. The optional linker connecting the antigenic peptide and the β2 microglobulin molecule is represented by a gray rod style, and the optional disulfide bond capture is represented by a black sphere. This figure was generated using Pymol and modified from the structures published in Clements et al., Proc Natl Acad Sci US A. 2005 Mar 1; 102(9): 3360-5 and Hansen et al., Trends Immunol. 2010 Oct; 31(10): 363-9.

[0077] Figure 2 : Example of a vector-based construct encoding a single-chain MHC Ib molecule suitable for therapeutic peptide-specific immunomodulation.

[0078] HLA-G1 and HLA-G5 are composed of three α domains (represented in black here), one non-covalently bound β2 microglobulin subunit (represented in dark gray here), and an antigenic peptide presented on HLA-G (short black arrow). HLA-G1 also contains a transmembrane domain and a short intracellular chain (not shown here). As shown in the figure, the α-3 domain can bind to the receptor ILT2 (see Shiroishi et al., Proc Natl Acad Sci US A. 2003 July 22; 100 (15): 8856-8861) and the receptor ILT4 (see Shiroishi et al., Proc Natl Acad Sci US A. 2006 Oct 31; 103 (44): 16412-7) on immune cells. Physiologically, these sequences form a non-covalently bound MHC class 1 complex. In order to simplify the purification of composite MHC Ib molecules, one or more protein tags (e.g., SpotTag, myc tag, and / or His(6x) tag) can be introduced. These tags are introduced in such a way that they can be optionally removed later by cutting using optional factor Xa or furin cleavage sites. In addition, antigenic peptides, β2-microglobulin, and MHC Ib α chains can be connected in sequence to improve stability. The vector map is generated using Snapgene Viewer software.

[0079] Figure 3 : The surrogate molecules of the recombinant polypeptide of the present invention induce Tregs that secrete IL10 in mice.

[0080] In this experiment, 100 μg of virus (Gp34) or ovalbumin (Ova) model peptide antigen, mouse H2-K bSurrogate molecules consisting of the α1 and α2 domains and the human HLA-G α3 domain and β-2-microglobulin were injected intraperitoneally (ip) into 12-week-old C57BL / 6 mice. Fourteen days later, mice were sacrificed and splenocytes isolated by Ficoll gradient were re-challenged with 5 μg / ml Gp34 or Ova peptide in a 48h standard mouse IL-10 ELISpot assay (Mabtech Mouse IL-10 HRP ELISpot Kit) (A).

[0081] A significant increase in IL-10-secreting regulatory T cells was detected only when restimulated with the peptide to which tolerance was induced by injection of the replacement molecule.

[0082] Figure 4 : The surrogate molecules of the recombinant polypeptide of the present invention can prevent EAE caused by CD8+T cells in mice.

[0083] In this MS mouse model, the model antigen ovalbumin (OVA) is expressed in oligodendrocytes under the control of the myelin basic protein (MBP) promoter (ODC-OVA). This results in the presentation of the OVA257-264 peptide on the H-2Kb MHC molecule on oligodendrocytes. OT-I mice express T cell receptors (OT-I) on their CD8+T cells, which can accurately recognize this peptide-MHC combination. When the CD8+T cells of these mice are transferred into 10-day-old ODC-OVA mice, these mice develop experimental autoimmune encephalomyelitis (EAE), whose pathogenesis and symptoms are similar to MS in many aspects (Na et al., Brain, Volume 131, Issue 9, September 2008, Pages 2353–2365). In this experiment, 500 μg of virus (Gp34) or ovalbumin (Ova) model peptide antigen, mouse H2-K b Alternative molecules consisting of the α1 and α2 domains and human HLA-G α3 domain and β-2-microglobulin or PBS alone were injected. EAE scoring was performed according to Bittner et al., J Vis Exp. 2014 Apr 15;(86):51275.

[0084] Only alternative molecules that induced ovalbumin tolerance could almost completely prevent EAE symptoms.

[0085] (A) Experimental design; (B) Results.

[0086] Figure 5 : The surrogate molecules of the recombinant polypeptides of the present invention can produce effective bystander immunosuppression.

[0087] This experiment tested whether a surrogate molecule of the Mog44 peptide could induce protective T cells capable of suppressing cytotoxic T cells directed against another peptide presented by the same cells. Figure 4 The molecule described in was injected into ODC-OVA mice at 250 μg / mouse together with OT-I cells. Figure 4 shown.

[0088] Although EAE symptoms could not be completely prevented using this lower dose of the replacement molecule, they were significantly reduced using both molecules that induced tolerance to either the directly targeted CD8 epitope (Ova_KbG) or to another epitope (Mog44) expressed on the same cells (Mog44_DbG).

[0089] (A) EAE score; (B): body weight.

[0090] Figure 6 :Some recombinant polypeptide replacement molecules of the present invention can selectively prevent CD4 + T cell-induced EAE.

[0091] (A) Experimental design: In this model, a strong myelin-specific autoimmune response was induced by administering MOG 35-55 peptide in combination with complete Freund's adjuvant (which activates CD4+ Th17 cells) and pertussis toxin (which makes the blood-brain barrier more permeable) (Protocol: Bittner et al., J Vis Exp. 2014 Apr 15; (86): 51275). Here, CD4+ cells and antibodies play a crucial role in the development of EAE (Tigno-Aranjuez et al., J Immunol November 1, 2009, 183 (9) 5654-5661). In addition, each mouse was injected with 100 μg of virus (Gp34) or two Mog peptide antigens (Mog37 or Mog44), mouse H2-D b Alternative molecules consisting of the α1 and α2 domains, and human HLA-G α3 domain and β-2-microglobulin or PBS alone were injected.

[0092] Mog44 peptide containing the replacement molecule significantly alleviated EAE symptoms (B) and weight loss (C).

[0093] Figure 7 : The Mog44 replacement molecule of the recombinant polypeptide of the present invention can prevent inflammation and CD8 T cell infiltration in the spinal cord. (A) Toluidine; (B) CD8-DAB.

[0094] 10 μm fresh frozen sections were stained with commercial toluidine 1× staining reagent for 1 h at room temperature. A large number of immune cell infiltrations were detected in EAE, but were blocked by Mog44_Db_G.

[0095] 10 μm fresh frozen sections were briefly dried at room temperature, fixed with acetone, blocked with 5% BSA, 10% normal goat serum in PBS, and stained with 1:100 anti-CD8 antibody and secondary antibody coupled with HRP and DAB solution (detailed method: Karikari et al., Brain Behav Immun. 2022 Jan 12; 101: 194-210). Mog35-55-induced EAE leads to CD8 + The cells infiltrated the spinal cord in large numbers, and this process was blocked by the MOG44_Db_G replacement molecule.

[0096] (A) Toluidine; (B) CD8-DAB.

[0097] Figure 8 : Detection of anti-MOG35-55 antibodies in Mog-EAE mice treated with the recombinant polypeptide replacement molecule of the present invention ("AIM Bio").

[0098] After mice were sacrificed, mouse serum was collected by cardiac puncture and diluted 1:50 in PBS. Overnight coating was performed using 10 μg / ml Mog35-55 in PBS, and then the wells were blocked with 1% BSA for 2 h, and then diluted serum was added and allowed to stand for 1 h. Anti-Mog35-55 antibodies were detected using the indicated secondary HRP-conjugated antibodies (diluted 1:5000 in PBS). Mog35-55-induced EAE was associated with high levels of Mog35-55-specific IgG autoantibodies, which were not detected in animals treated with 100 μg MOG44_Db_G replacement molecules.

[0099] Fig. 9 : List of human MS and MOGAD recombinant peptide candidates.

[0100] Myelin (MAG, MBP, MOG, PLP) peptides and MHC class I presenting molecules are as follows:

[0101]

[0102]

[0103] It further shows which combinations of myelin peptides and antigen presenting MHC class I α1 and α2 domains (HLAG = HLA-G, A2G = HLA-A2 presenting domain + HLA-G α3 domain) are expressed / prepared, ELISpot-based prioritization in healthy blood donors (e.g. Fig.10 Good results can be produced by using the predictions of the PCR products (shown in Figure 2) or AlphaFold2. His indicates a 6-histidine tag and Spt indicates a Spot-Tag.

[0104] Fig.10 : The recombinant polypeptide containing VLLAVLPVL antigen ("Mog157_A2G") of the present invention upregulates CD8 Treg in healthy blood donors.

[0105] AIM Biologicals mediated in vitro Treg induction is as follows:

[0106] PBMCs from healthy donors were purified by density centrifugation of leukocytes from the leukocyte attenuation chamber using Ficoll. Cells were centrifuged at 1200×g for 20 min without interruption, and then the mesophase rings were collected and washed with 1× PBS (5 min, 300×g). PBMCs were frozen until further use.

[0107] PBMCs were thawed 1 day before PBMC pulse (d-1) and stored in 5 ml X-VIVO 15 medium containing 5% human AB serum in wells of 6-well plates at 37°C overnight.

[0108] On the next day (d0), the cells were counted and suspended in X-VIVO 15 complete medium (5% hAB serum and cytokine mixture: 20 ng / ml hIL-2, 20 ng / ml hGM-CSF, 10 ng / ml hIL-4 and 10 ng / ml hTGF-b1) at a cell density of 3 × 10 6 cells / ml. In the experiment, 3×10 6 Each cell was seeded in the corresponding wells of a 12-well plate with a final volume of 1000 μl of X-VIVO complete medium containing a cytokine cocktail and 5 μg / ml AIMBio molecules or corresponding controls.

[0109] On day 3, 1 ml of complete medium (containing cytokines) was added, and on day 6, a second pulse of stimulation with 5 μg / ml AIM Bio molecules was performed (after removing the medium). On days 7, 10, and 12, 1 ml of complete medium (containing cytokines) was added.

[0110] On day 13, the ELISPOT plate PVDF membrane was activated with 50 μl / well EtOH (35% v / v) for 1 min, and then washed 5 times with 200 μl distilled sterile water. The plate was coated with 100 μl / well anti-hIL10 (clone 9D-7, diluted 1:500 in PBS, sterile filtered) at 4°C overnight. The next day, the unbound coating antibody was removed, 5 washing steps were performed with 200 μl PBS, and 200 μl blocking buffer (X-VIVO 15 5% hAB serum) was added, and the plate was incubated at room temperature for 30 min-2 h.

[0111] On day 14, 200,000 cells were seeded in each well of an ELISPOT plate in duplicate, including a negative control (cells plus PBS) and a positive control (eg, LPS).

[0112] Secondary antibody preparation: 1 μg / ml aIL-10-biotinylated antibody (1:1000 dilution) and horseradish peroxidase-conjugated streptavidin (0.5% BSA / PBS, 1:750 dilution) in 0.5% BSA / 1×PBS. The tetramethylbenzidine solution was filtered using a 0.45 μm filter and stored at 4°C until use.

[0113] Remove the cell supernatant and wash five times with 100 μl PBS. Finally, remove the excess buffer with paper.

[0114] 25 μl of diluted HRP-streptavidin (1:750) was added to each well, incubated for 1 h at room temperature in the dark, and then washed five times with sterile 1× PBS.

[0115] Add 100 μl of filtered TMB substrate to each well and let stand for 15-25 min until blue spots appear. Rinse the wells thoroughly with tap water to stop the reaction.

[0116] Remove the board's plastic drain and rinse the bottom and sides of the board with tap water and allow to dry.

[0117] MOG157_A2G_Spt induced at least a 30% increase in IL-10-secreting Tregs in 75% of healthy blood donors.

[0118] Fig.11 : Figure 8 Control experiments showed that total IgG was not reduced by MOG47_Db_G surrogate molecule treatment. Easy-Titer TM Total IgG was quantified using the Human IgG (γ chain) Detection Kit (Thermo Fisher). Figure 8 Together, they show that selective antibody responses can be inhibited using single-chain MHC Ib molecules.

[0119] Fig.12 : Stability of purified single-chain MHC Ib molecules. After purification, the single-chain MHC Ib molecules were analyzed for stability after 1 and 3 freeze-thaw cycles, storage at room temperature for 5 days, and heating to 50°C for 30 min. For this purpose, A) 12% polyacrylamide gels were stained with Coomassie Brilliant Blue using 2 μg AIM Bio, and B) aHLA-G Western blotting was performed under non-reducing conditions using 2A12 aHLA-G antibody (1:1000) and 1 μg protein. Both monomers and dimers were detected.

[0120] Fig.13 : Single-chain MHC Ib molecules are thermally stable. For thermal shift analysis (TSA), 3 μg of the corresponding single-chain MHC Ib molecules or Motavizumab as a control molecule were diluted to a volume of 25 μl with PBS and 5×SYPRO Orange dye (stock solution 5000×, final concentration: 5×). The melting curve program was set up on the StepOnePlus instrument using StepOnePlus software 2.3. The starting temperature was 25°C for 1 min, and then the temperature was increased to a final temperature of 95°C at a rate of 1°C per minute for 2 min, thereby measuring autofluorescence in arbitrary units. The data have been exported and graphed in Prism V7.04. To determine the melting temperature (Tm), the Boltzman sigmoid function was used.

[0121] Fig.14 :Single-chain MHC Ib molecules induce Treg in a dose-dependent manner. OT-I mice were intraperitoneally injected with the indicated amount of single-chain H2_K b α1+2, HLA-Gα3 domain human β-2-microglobulin and the indicated peptide constructs, or vehicle (PBS). In these mice, Ova is the homologous peptide of OT-I TCR and Gp34 is an unrelated virus-derived control peptide. After 14 days, mice were sacrificed and IL10 secreting cells in splenocytes were tested in the recall mouse IL-10 ELISpot (200,000 cells per well, MabTech mouse IL-10 ELISpot kit, supplemented with 5μg / ml of the indicated peptide or PBS alone, 48h). When 50μg and 500μg of mouse-adapted Ova_KbG were injected, a clear induction of IL-10 secreting cells reactive to the Ova peptide was observed.

[0122] Fig.15: Single-chain MHC Ib molecules inhibit T cell lysis in a dose-dependent manner. 10mio OT-1 / ml, cultured for 3 days in the presence of single-chain MHC Ib molecules, 37°C, shaking at 125rpm, OT-1:Panc02 ratio of 50:1.

[0123] method:

[0124] Splenocyte isolation and treatment.

[0125] OT1 / BL6 mice were sacrificed, spleen cells were collected and washed once in RPMI 5% FCS. Red blood cells were removed by treatment with 2ml 1× sterile RBC lysis buffer for 3min. Cells were cultured at high density (10mio cells / ml) for 72h in RPMI 10% FCS medium containing GMCSF 20ng / mL, IL-2 20ng / ml and IL-4 10ng / ml, and increasing doses of Ova_KbG. The cells were then scraped from the culture dish and CD8+ cells were purified by magnetic beads.

[0126] Luciferase assay (48h)

[0127] Use a sterile 96-well white plate. Load Panc02 fluc+ target cells with 20μg / ml Ova peptide (SIINFEKL) and shake at 500rpm for 60min at 37°C. Mix effector CD8+ T cells with PancO2 target cells (5000 target cells) at a ratio of 50:1 and add fluorescein. Measure luminescence at 0h, 24h, and 48h.

[0128] Fig.16: Serum cytokines of EAE-ODC Ova mice. Serum cytokines of EAE-ODC Ova mice were measured using the Th1 / Th210plex Flowcytomix Kit (eBioscience) according to the manufacturer's instructions. The kit is used to simultaneously detect mouse granulocyte macrophage colony stimulating factor (GMCSF), interleukin 1α (IL-1a), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 17 (IL-17), and tumor necrosis factor (TNF) in a single sample. The array kit provides a mixture of ten capture beads with different fluorescence intensities, which have been coated with specific capture antibodies for each cytokine. The beads coated with the ten specific capture antibodies are mixed together. Subsequently, 25 μL of mixed capture beads, 25 μL of unknown serum sample or standard dilution, and 25 μL of phycoerythrin (PE) detection reagent were added to each well of a 96-V bottom plate and incubated at room temperature in the dark for 2 h. The samples were washed with 1 mL of wash buffer for 5 min and then centrifuged. The supernatant was discarded and the beads were resuspended in 200 μL of buffer. Using Attune TM Samples were measured on an NxT flow cytometer and analyzed using Attune flow cytometer software (Thermo Fisher Scientific).

[0129] Fig.17 : Immunofluorescence analysis of the spinal cord in the MOG-induced EAE model.

[0130] A, B: Caspase 3 infiltration in the spinal cord of MOG-induced EAE. A: images; B: quantification.

[0131] C, D: MOG-induced EAE spinal cord white matter injury. C: image; D: quantification.

[0132] E, F: CD3 infiltration in the spinal cord of MOG-induced EAE. E: images; F: quantification.

[0133] Fig.18 : IL10 puncta increased after MOG157_A2G treatment. DETAILED DESCRIPTION OF THE INVENTION

[0135] Definition and general techniques

[0136] Unless otherwise specified below, the terms used in the present invention should be understood according to the ordinary meaning known to those skilled in the art. All publications, patents and patent applications cited herein are fully incorporated herein by reference. Publications mentioned herein can be cited by specifying complete literature references in the text.

[0137] All proteins of the present invention, including the recombinant polypeptides of the present invention, can be obtained by methods known in the art. These methods include methods for producing recombinant polypeptides. The recombinant polypeptides of the present invention can be expressed in recombinant host cells according to the present invention. The recombinant host cells of the present invention are preferably mammalian cells, such as CHO and HEK cells.

[0138] It should be understood that the recombinant polypeptide of the present invention is intended to optionally include a secretion signal peptide sequence. Similarly, the recombinant polypeptide of the present invention is also intended to optionally include an affinity tag, such as to facilitate purification, and an optional protease cleavage site between the tag and the polypeptide, such as to facilitate removal of the tag by protease cleavage.

[0139] It should also be understood that any amino acid sequence mentioned herein is intended to cover not only the unmodified amino acid sequence, but also typical post-translational modifications of these amino acid sequences that occur in cellular expression systems known in the art (e.g., glycosylation or deamidation of amino acids, cleavage of specific amino acids or other post-translational modifications), including mammalian cells, such as CHO and HEK cells.

[0140] Likewise, it is to be understood that the recombinant polypeptides of the present invention are intended to optionally include the corresponding propeptides.

[0141] It should also be understood that the recombinant polypeptide of the present invention can be in its soluble form or in its membrane-bound form. Whether the recombinant polypeptide is "soluble" under these conditions can be determined by methods known in the art, such as by measuring the turbidity of the recombinant polypeptide under the above-mentioned reference conditions. As used herein, soluble means that at least 95% of the recombinant polypeptide is determined to be soluble under these reference conditions.

[0142] Single-chain MHC molecules can be stored, for example, at -80°C in PBS (with or without 0.1% human albumin as a carrier, depending on the protein concentration), or at -20°C in 50% glycerol.

[0143] According to the present invention, the MHC molecule is preferably a human MHC molecule.

[0144] The recombinant polypeptide of the present invention is preferably an isolated recombinant polypeptide.

[0145] It should be understood how to prepare recombinant polypeptides that can bind and present peptide antigens according to the present invention. For example, peptide antigen binding domains, such as α1 and α2 domains are well known, and these domains can be modified. The ability of peptide antigens to bind to polypeptides and MHC molecules according to the present invention can be determined by techniques known in the art, including but not limited to exploratory methods, such as MHC peptide elution, followed by mass spectrometry and computer bioinformatics prediction, and confirmatory methods, such as MHC peptide polymer binding and stimulation tests.

[0146] According to the present invention, the recombinant polypeptide, pharmaceutical composition and kit of the present invention are preferably suitable for use in human patients.

[0147] According to the present invention, the recombinant polypeptide, pharmaceutical composition and kit of the present invention are preferably suitable for treating multiple sclerosis (MS), MOG antibody disease or MOG antibody-positive neuromyelitis optica in human patients.

[0148] According to the present invention, the recombinant polypeptides, pharmaceutical compositions and kits of the present invention are preferably suitable for inducing immune tolerance against human myelin-oligodendrocyte glycoprotein (MOG), human myelin basic protein (MBP), human myelin associated glycoprotein (MAG), or human myelin proteolipid protein (PLP1), for example, in human patients.

[0149] It should be understood that according to the present invention, the recombinant polypeptides, pharmaceutical compositions and kits of the present invention are stable.

[0150] It is understood that, for the peptide antigens used in the present invention, any length of these peptide antigens referred to herein (e.g., "length of 7 to 11 amino acids") refers to the length of the peptide antigen itself. Therefore, the length of the peptide antigen referred to herein does not include additional amino acids that do not belong to the peptide antigen (the length conferred, such as additional amino acids from possible linker sequences, etc.).

[0151] According to the present invention, each occurrence of the term "comprising" may optionally be replaced by "consisting of".

[0152] Methods and techniques

[0153] Generally, unless otherwise specified herein, the methods used in the present invention (e.g., cloning methods or methods related to antibodies) are performed according to procedures known in the art, such as those described in Sambrook et al. ("(:A Laboratory Manual.", 2Nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1989), Ausubel et al. ("Current Protocols in Molecular Biology." Greene Publishing Associates and Wiley Interscience; New York 1992), and Harlow and Lane ("Antibodies:A Laboratory Manual" Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1988), all of which are incorporated herein by reference.

[0154] Protein-protein binding, e.g. binding of an antibody to its respective target protein, can be assessed by methods known in the art. Protein-protein binding is preferentially assessed by surface plasmon resonance spectroscopy measurements.

[0155] For example, the binding of the MHC class b molecule or recombinant polypeptide according to the present invention to its receptor, including ILT2 and ILT4, is preferably evaluated by surface plasmon resonance spectroscopy. More preferably, the binding of the MHC class Ib molecule or recombinant polypeptide according to the present invention to its receptor is evaluated by surface plasmon resonance measurement at 25°C. Shiroishi et al. describe suitable conditions for such surface plasmon resonance measurement (Shiroishi et al., Proc Natl Acad Sci USA. 2003 July 22; 100 (15): 8856-8861.).

[0156] Sequence alignment according to the present invention is performed using the BLAST algorithm (see Altschul et al. (1990) "Basic local alignment search tool." Journal of Molecular Biology 215. p. 403-410.; Altschul et al.: (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25: 3389-3402.). Suitable parameters for sequence alignment of short peptides using the BLAST algorithm, which are suitable for peptide antigens according to the present invention, are known in the art. Most software tools using the BLAST algorithm automatically adjust the parameters for sequence alignment of short input sequences. In one embodiment, the following parameters are used: Max target sequences 10; Word size 3; BLOSUM 62 matrix; gap costs: existence 11, extension 1; conditional compositional score matrix adjustment. Thus, terms such as "identity" or "identical" when used in connection with a sequence preferably refer to identity values ​​derived using the BLAST algorithm.

[0157] Preparation of the pharmaceutical composition of the present invention

[0158] The pharmaceutical composition of the present invention is prepared according to known pharmaceutical composition preparation standards.

[0159] For example, the pharmaceutical composition should be prepared in a manner that enables it to be easily stored and administered.Thus, the pharmaceutical composition of the present invention may comprise pharmaceutically acceptable components, such as carriers, excipients and / or stabilizers.

[0160] These pharmaceutically acceptable components are non-toxic in the amounts used when the pharmaceutical composition is administered to human patients. The pharmaceutically acceptable components added to the pharmaceutical composition may depend on the chemical nature of the active ingredients present in the composition, the specific use of the pharmaceutical composition and the route of administration.

[0161] Generally, pharmaceutically acceptable components related to the present invention are used according to the existing knowledge in the art, for example, see Remington's Pharmaceutical Sciences, Ed. AR Gennaro, 20th edition, 2000, Williams & Wilkins, PA, USA. Pharmaceutical compositions comprising nucleic acids (e.g., RNA) of the present invention can also be formulated according to the existing knowledge in the art, for example, using liposome formulations targeting dendritic cells.

[0162] Peptide antigens according to the present invention

[0163] The peptide antigens that can be used according to the present invention include the peptide antigens defined above, and there is no particular limitation except that they can be presented on MHC molecules. It should be understood that the "peptide antigen presented by the recombinant polypeptide" referred to in the present invention refers to the peptide antigen presented by the recombinant polypeptide to human T cells (if such T cells exist) in a manner that binds to the T cell receptor on the human T cells.

[0164] As is known in the art, peptides that can be presented on MHC molecules can be produced (see, e.g., Rammensee, Bachmann, Emmerich, Bachor, SYFPEITHI:database for MHCligands andpeptide motifs.Immunogenetics.1999Nov;50(3-4):213-9;Pearson et al.MHC classI-associated peptides derive from selective regions of the human genome.JClin Invest.2016Dec 1;126(12):4690-4701;and Rock,Reits,Neefjes.PresentYourself! By MHC Class I and MHC Class II Molecules.Trends Immunol.2016Nov;37(11)::724-737).

[0165] Peptide antigens are well known in the art. Generally, peptide antigens according to the present invention are capable of binding to MHC class I proteins. It will be appreciated by those skilled in the art that for each MHC class Ib molecule or polypeptide capable of presenting a peptide according to the present invention, a peptide antigen capable of binding to said MHC class Ib molecule or recombinant polypeptide will preferably be used. These peptide antigens can be selected based on methods known in the art.

[0166] The binding of a peptide antigen to an MHC class Ib molecule according to the present invention or a polypeptide capable of binding to a peptide antigen can be assessed by methods known in the art, such as the following method:

[0167] Rammensee,Bachmann,Emmerich,Bachor, SYFPEITHI:database forMHC ligands and peptide motifs.Immunogenetics.1999Nov;50(3-4):213-9;

[0168] Pearson et al.MHC class I-associated peptides derive from selective regions of the human genome.J Clin Invest.2016Dec 1;126(12):4690-4701; and

[0169] Rock,Reits,Neefjes.Present Yourself! By MHC Class I and MHC Class IIMolecules.Trends Immunol.2016Nov;37(11):724-737.

[0170] These methods include experimental approaches and methods for predicting peptide antigen binding.

[0171] Anchor residues for anchoring peptide antigens to MHC class I molecules and ensuring binding of peptide antigens to MHC class I molecules are known in the art.

[0172] In a preferred embodiment according to all embodiments of the present invention, the peptide antigen used according to the present invention comprises any anchor or preferred amino acid residues at positions predicted for MHC class I molecules.

[0173] Preferably, such predictions are performed as described in any of the following publications:

[0174] -Rammensee et al, SYFPEITHI: database for MHCligands and peptidemotifs. Immunogenetics (1999) 50:213-219

[0175] -Nielsen et al,Protein Sci(2003)12:1007-1017

[0176] -Neefjes et al. Nat Rev Immunol.2011Nov 11;11(12):823-36

[0177] -Diehl et al.Curr Biol.1996Mar 1;6(3):305-14,

[0178] -Lee et al.Immunity.1995Nov;3(5):591-600.

[0179] -Desai&Kulkarni-Kale,T-cell epitope prediction methods:anoverview.Methods Mol Biol. 2014;1184:333-64.

[0180] -Jumper et al.Highly accurate protein structure prediction withAlphaFold.Nature2021;596:583–589

[0181] In the present invention, the peptide antigen is derived from human myelin-oligodendrocyte glycoprotein (MOG), human myelin basic protein (MBP), human myelin associated glycoprotein (MAG), or human myelin proteolipid protein (PLP1).

[0182] It should be understood that the non-anchor amino acid residues of the peptide antigen of the present invention may or may not contain conservative substitutions relative to the corresponding amino acid sequences of the peptide antigens of human myelin-oligodendrocyte glycoprotein (MOG), human myelin basic protein (MBP), human myelin-associated glycoprotein (MAG) or human myelin proteolipid protein (PLP1), preferably no more than two conservative substitutions, and more preferably one conservative substitution.

[0183] The peptide antigens of the present invention are preferably composed of naturally occurring amino acids. However, non-naturally occurring amino acids, such as modified amino acids, may also be used. For example, in one embodiment, the peptide antigens of the present invention include a peptidomimetic of a specified peptide antigen amino acid sequence of human myelin-oligodendrocyte glycoprotein (MOG), human myelin basic protein (MBP), human myelin associated glycoprotein (MAG), or human myelin proteolipid protein (PLP1).

[0184] Methods for the synthesis of peptide antigens, including peptide antigens according to the present invention, are well known in the art.

[0185] Therapeutic applications of the invention

[0186] The recombinant polypeptide of the present invention can be used to treat multiple sclerosis, MOG antibody disease and MOG antibody-positive neuromyelitis optica.

[0187] The treatment can be a treatment by inducing myelin-specific regulatory T cells. Because such regulatory T cells (e.g., CD8 positive regulatory T cells) are activated in myelin structures, they can confer target cell protection to resist cytotoxic T cells that recognize the same or another myelin antigen. Regulatory T cells (e.g., CD8 positive regulatory T cells) are known in the art and can be detected, for example, by their secretion of IL-10.

[0188] Although CD8 positive regulatory T cells are not as well known as CD4CD25 regulatory T cells, they are considered even more potent. See, for example:

[0189] Junfeng Liu, Dacan Chen, Golay D. Nie and Zhenhua Dai CD8+CD122+T-Cells: A Newly Emerging Regulator with Central Memory CellPhenotypes. Front.Immunol.doi:10.3389 / fimmu.2015.00494; and Niederlova, V., Tsyklauri, O., Chadimova, T.and Stepanek,O.(2021),CD8 + Tregs revisited: Aheterogeneous population with different phenotypes andproperties. Eur.J.Immunol.,51:512-530.https: / / doi.org / 10.1002 / eji.202048614

[0190] While these cells are characterized by the expression of CD122 and CD8 in mice, the corresponding cells in humans are described as being positive for CD8 and CXCR3. See, for example:

[0191] Shi Z, Okuno Y, Rifa'i M, Endharti AT, Akane K, Isobe K, et al. Human CD8+CXCR3+T cells have the same function as murine CD8+CD122+Treg. Eur J Immunol (2009) 39:2106–2119.doi:10.1002 / eji.200939314).

[0192] The treatment may be a treatment that reduces the level of autoantibodies against human myelin-oligodendrocyte glycoprotein in plasma or cerebrospinal fluid. The human patient may be a patient whose plasma or cerebrospinal fluid has autoantibodies against myelin-oligodendrocyte glycoprotein before the start of treatment.

[0193] According to the present invention, autoantibodies can be detected by various methods known in the art. The preferred method is a cell-based assay (CBA), in which the suspected target antigen of the autoantibody (e.g., myelin-oligodendrocyte glycoprotein) is overexpressed in HEK293 or CHO cells, and the cells are then incubated with serum or cerebrospinal fluid, usually at room temperature for 1 h. Simulated transfected sister cells are used as controls. Autoantibodies bound to cells are detected using different fluorescently labeled anti-human specific secondary antibodies, which can recognize total human IgG (heavy chain and light chain), IgG-Fc (constant chain) or IgG1. Binding can be quantified by visual scoring of flow cytometry (CBA-FACS) or immunofluorescence microscopy evaluation (CBA-IF), usually by titration. In most established cell-based MOG antibody detection methods, the a1 isomer of MOG with 218 amino acids is used, although there is also an alternative in which a truncated version of MOG containing only extracellular immunoglobulins and transmembrane domains is tested. Other methods such as enzyme-linked immunosorbent assay (ELISA) or Western blotting can also be used, but are generally less sensitive because they may not detect conformation-sensitive antibodies. Suitable methods are described in Waters, P., Pettingill, P. & Lang, B. Detection methods for neuroautoantibodies. Handb. Clin. Neurol. 133, 147–163 (2016).

[0194] For a detailed overview of myelin oligodendrocyte glycoprotein (MOG) antibodies, see Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019 Feb; 15(2): 89-102. doi: 10.1038 / s41582-018-0112-x. PMID: 30559466.

[0195] sequence

[0196] The preferred amino acid sequences mentioned in the present application can be independently selected from the following sequences. These sequences are represented in the order from N-terminus to C-terminus; and are represented by single-letter amino acid codes.

[0197] Exemplary sequences as part of the recombinant polypeptides of the invention:

[0198] Optional leader peptide (deleted from recombinant polypeptide due to processing during cellular expression): e.g. MSRSVALAVLALLSLSGLEA (SEQ ID NO: 1)

[0199] Peptide antigen: any MHC class I peptide corresponding to the MHC class I α1 & 2 domains, for example, VLLAVLPVL (SEQ ID NO: 2) (most preferred)

[0200] First linker: for example, GGGGSGGGGSGGGGS (SEQ ID NO: 3) or GCGASGGGGSGGGGS (SEQ ID NO: 4)

[0201] beta-2 microglobulin, such as:

[0202] IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKD WSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM (SEQ ID NO: 5, human β2 microglobulin)

[0203] Second connector, for example:

[0204] GGGGSGGGGSGGGGSGGGGS(SEQ ID NO:6)

[0205] α1 & 2 domains from human HLA-G or other MHC class I α1 & 2 domains suitable for presenting the selected antigenic peptide, in the DT variant Y84 can be C

[0206] For example, the α1&2 domains from human HLA-G: For example:

[0207] GSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVRFDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQTLRGCYNQSEASSHTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAANVAEQRRAYLEGTCVEWLHRYLENGKEMLQRA(SEQ ID NO:7)

[0208] Or: Human HLA-A2α1&2 domains: For example:

[0209] GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGCYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRT(SEQ ID NO:8)

[0210] Human HLA-G α3 domain (or any MHC class Ib α3 domain, such as HLA-F, which also interacts with ILT2 and ILT4 receptors), for example:

[0211] DPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGT FQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDL (SEQ ID NO: 9; sequence of HLA-Gα3).

[0212] Note: The following underlined amino acids of this sequence are involved in the interaction with ILT2 or ILT4 receptors:

[0213] DPPKTHVTHH PVFDYE ATLRCWALGFYPAEIILTWQRDGEDQTQD V ELVETRPAGDGT FQKWAAV VVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDL

[0214] In addition, a shorter form of the human HLA-Gα3 domain may be used that lacks the alternative C-terminal amino acid sequence from intron 4 (SKEGDGGIMSVRESRSLSEDL; SEQ ID NO: 20), namely:

[0215] DPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGT FQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRW(SEQ ID NO:21),

[0216] Factor Xa restriction site: IEGRTGTKLGP (SEQ ID NO: 10)

[0217] SpotTag: PDRVRAVSHWSSC(SEQ ID NO:11)

[0218] Myc tag: EQKLISEEDL (SEQ ID NO: 12)

[0219] His tag: HHHHHH* (SEQ ID NO: 13)

[0220] Spacer sequence: for example NSAVD (SEQ ID NO: 14) or GS

[0221] Other (alternative) exemplary peptide antigens that may be part of the recombinant polypeptide of the present invention are as follows:

[0222] Table 1: Further preferred peptide antigens

[0223]

[0224] Examples of recombinant polypeptides of the invention (with optional leader peptides):

[0225] MSRSVALAVLALLSLSGLEAVLLAVLPVLGCGASGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDMGGGGSGGGGSGGGGSGGGGSGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVRFDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQTLRGCYNQSEASSHTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAANVAEQRRAYLEGTCVEWLHRYLENGKEMLQRADPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC*(SEQ ID NO:15; Note that the asterisk indicates the stop codon)

[0226] Note that the peptide antigen sequence of the above-mentioned full-length recombinant polypeptide (here: VLLAVLPVL) can be replaced by any peptide antigen sequence of the present invention, that is, replaced by any peptide antigen presented by the recombinant polypeptide, wherein the peptide antigen is a peptide of human myelin-oligodendrocyte glycoprotein (MOG), human myelin basic protein (MBP), human myelin associated glycoprotein (MAG), or human myelin proteolipid protein (PLP1). That is, the recombinant polypeptide of the present invention can be composed of the following sequence, the composition of which is a peptide antigen, which is a peptide of human myelin-oligodendrocyte glycoprotein (MOG), human myelin basic protein (MBP), human myelin associated glycoprotein (MAG) or human myelin proteolipid protein (PLP1) (for example, SEQ ID NO: 2, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 32, and SEQ ID NO:33), followed by the following sequence GCGASGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDMGGGGSGGGGSGGGGSGGGGSGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVRFDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQ TLRGCYNQSEASSHTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAANVAEQRRAYLEGTCVEWLHRYLENGKEMLQRADPPKTHVTHHPVFDY EATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC*(SEQ ID NO:16; note that the asterisk indicates the stop codon)

[0227] The recombinant polypeptides of the present invention may also contain an optional leader peptide as exemplified above.

[0228] The receptors ILT2 (also known as LILRB1) and ILT4 (also known as LILRB2) are known in the art. Preferred sequences of these receptors according to the invention are as follows:

[0229] ILT2:

[0230] MTPILTVLICLGLSLGPRTHVQAGHLPKPTLWAEPGSVITQGSPVTLRCQGGQETQEYRLYREKKTALWITRIPQELVKKGQFPIPSITWEHAGRYRCYYGSDTAGRSESSDPLELVVTGAYIKPTLSAQPSPVVNSGGNVILQCDSQVAFDGFSLCKEGEDEHPQCLNSQPHARGSSRAIFSVGPVSPSRRWWYRCYAYDSNSPYEWSLPSDLLELLVLGVSKKPSLSVQPGPIVAPEETLTLQCGSDAGYNRFVLYKDGERDFLQLAGAQPQAGLSQANFTLGPVSRSYGGQYRCYGAHNLSSEWSAPSDPLDILIAGQFYDRVSLSVQPGPTVASGENVTLLCQSQGWMQTFLLTKEGAADDPWRLRSTYQSQKYQAEFPMGPVTSAHAGTYRCYGSQSSKPYLLTHPSDPLELVVSGPSGGPSSPTTGPTSTSGPEDQPLTPTGSDPQSGLGRHLGVVIGILVAVILLLLLLLLLFLILRHRRQGKHWTSTQRKADFQHPAGAVGPEPTDRGLQWRSSPAADAQEENLYAAVKHTQPEDGVEMDTRSPHDEDPQAVTYAEVKHSRPRREMASPPSPLSGEFLDTKDRQAEEDRQMDTEAAASEAPQDVTYAQLHSLTLRREATEPPPSQEGPSPAVPSIYATLAIH(SEQ ID NO:17)

[0231] ILT4:

[0232] (SEQ ID NO:18)

[0233] The sequences of human myelin-oligodendrocyte glycoprotein (MOG), human myelin basic protein (MBP), human myelin associated glycoprotein (MAG) or human myelin proteolipid protein (PLP1) are known in the art. The preferred amino acid sequences of human myelin-oligodendrocyte glycoprotein (MOG), human myelin basic protein (MBP), human myelin associated glycoprotein (MAG) or human myelin proteolipid protein (PLP1) are as follows:

[0234] Human Myelin-Oligodendrocyte Glycoprotein (MOG):

[0235] >NP_996532.2myelin-oligodendrocyte glycoprotein isoform alpha1precursor[Homo sapiens]

[0236] MASLSRPSLPSCLCSFLLLLLLQVSSSYAGQFRVIGPRHPIRALVGDEVELPCRISPGKNATGMEVGWYRPPFSRVVHLYRNGKDQDGDQAPEYRGRTELLKDAIGEGKVTLRIRNVRFSDEGGFTCFFRDHSYQEEAAMELKVEDPFYWVSPGVLVLLAVLPVLLLQITVGLIFLCLQYRLRGKLRAEIENLHRTFDPHFLRVPCWKITLFVIVPVLGPLVALIICYNWLHRRLAGQFLEELRNPF

[0237] (SEQ ID NO:19)

[0238] Human myelin basic protein (MBP):

[0239] >NP_001020252.1 myelin basic protein isoform 1 [Homo sapiens]

[0240] MASQKRPSQRHGSKYLATASTMDHARHGFLPRHRDTGILDSIGRFFGGDRGAPKRGSGKVPWLKPGRSPLPSHARSQPGLCNMYKDSHHPARTAHYGSLPQKSHGRTQDENPVVHFFKNIVTPRTPPPSQGKGRGLSLSRFSWGAEGQRPGFGYGGRASDYKSAHKGFKGVDAQGTLSKIFKLGGRDSRSGSPMARR

[0241] (SEQ ID NO:22)

[0242] Human myelin-associated glycoprotein (MAG):

[0243] >NP_002352.1 myelin-associated glycoprotein isoform a precursor [Homo sapiens]

[0244] MIFLTALPLFWIMISASRGGHWGAWMPSSISAFEGTCVSIPCRFDFPDELRPAVVHGVWYFNSPYPKNYPPVVFKSRTQVVHESFQGRSRLLGDLGLRNCTLLLSNVSPELGGKYYFRGDLGGYNQYTFSEHSVLDIVNTPNIVVPPEVVAGTEVEVSCMVPDNCPELRPELSWLGHEGLGEPAVLGRLREDEGTWVQVSLLHFVPTREANGHRLGCQASFPNTTLQFEGYASMDVKYPPVIVEMNSSVEAIEGSHVSLLCGADSNPPPLLTWMRDGTVLREAVAESLLLELEEVTPAEDGVYACLAENAYGQDNRTVGLSVMYAPWKPTVNGTMVAVEGETVSILCSTQSNPDPILTIFKEKQILSTVIYESELQLELPAVSPEDDGEYWCVAENQYGQRATAFNLSVEFAPVLLLESHCAAARDTVQCLCVVKSNPEPSVAFELPSRNVTVNESEREFVYSERSGLVLTSILTLRGQAQAPPRVICTARNLYGAKSLELPFQGAHRLMWAKIGPVGAVVAFAILIAIVCYITQTRRKKNVTESPSFSAGDNPPVLFSSDFRISGAPEKYESERRLGSERRLLGLRGEPPELDLSYSHSDLGKRPTKDSYTLTEELAEYAEIRVK

[0245] (SEQ ID NO:23)

[0246] Human myelin proteolipid protein (PLP1):

[0247] >NP_000524.3 myelin proteolipid protein isoform 1 [Homo sapiens]

[0248] MGLLECCARCLVGAPFASLVATGLCFFGVALFCGCGHEALTGTEKLIETYFSKNYQDYEYLINVIHAFQYVIYGTASFFFLYGALLLAEGFYTTGAVRQIFGDYKTTICGKGLSATVTGGQKGRGSRGQHQAHSLERV CHCLGKWLGHPDKFVGITYALTVVWLLVFACSAVPVYIYFNTWTTCQSIAFPSKTSASIGSLCADARMYGVLPWNAFPGKVCGSNLLSICKTAEFQMTFHLFIAAFVGAAATLVSLLTFMIAATYNFAVLKLMGRGTKF

[0249] (SEQ ID NO:24)

[0250] The present invention is further illustrated by the following non-limiting examples. Example

[0251] Embodiment 1:

[0252] Method for producing the recombinant polypeptide of the present invention

[0253] -In Expi-293 TM Expi-293F cells (ThermoFisher) were grown in expression medium (Thermo Fisher): Expifectamine TM 293 transfection kit (Thermo Fisher), DNA was complexed with Expifectamine using Opti-MEM (Thermo Fisher), and 1 μg of DNA was transfected into 2.5×10 6 cells / ml, after 18-20h, enhancer was added according to the protocol, and supernatant was harvested after 4-6 days (37°C, 8% CO2 humidified incubator), 19mm 2 The culture was shaken at 125 rpm on an orbital shaker.

[0254] -Spot-tag protein purification: Spot-Cap resin equilibration: transfer the required amount of slurry to an appropriate tube, pellet the beads by centrifugation (4°C, 4 min, 2500 g), remove and discard the supernatant, add 10 bed volumes of PBS (pre-cooled) to the beads, invert to mix, pellet the beads by centrifugation (4°C, 4 min, 2500 g), remove and discard the supernatant, and repeat 2 times.

[0255] - Add the required volume of beads to the supernatant, incubate at 4°C on a rotator, wash the beads by repeated centrifugation (4°C, 4 min, 2500 g), and then remove the supernatant.

[0256] - Prepare 500 μM Spot-peptide solution in PBS, remove the supernatant, and incubate with 1 / 3rd Spot-peptide solution for 5-10 min.

[0257] The beads were pelleted by centrifugation. Protein concentration was performed using an Amicon Ultra-4 centrifugal filter (15 kDa cutoff) and Spot-peptide was removed using a 15 kDa Amicon cutoff column.

[0258] Amicon Ultra-4 centrifugal filters (15 kDa cut-off) were rinsed with PBS and then with 0.1 N NaOH (centrifugation at 4000 g, 4°C) to remove traces of glycerol.

[0259] ELISPOT:

[0260] 1) Cell culture

[0261] A) PBMC isolation (under laminar flow hood)

[0262] To isolate peripheral blood mononuclear cells (PBMC), density centrifugation was performed using leukocytes from a leukocyte attenuation chamber and a density gradient medium (e.g., Ficoll or ROTI Sep 1077). The cells were centrifuged at 1200 × g for 20 min without interruption, and then the mesophase ring was collected and washed with 1 × PBS (5 min, 300 × g). PBMC were frozen until further use.

[0263] B) PBMC pulse stimulation (under laminar flow hood)

[0264] PBMCs were thawed 1 day (d-1) before PBMC pulse stimulation and stored in 5 ml X-VIVO 15 medium containing 5% human AB serum at 37°C overnight in wells of a 6-well plate.

[0265] On the next day (d0), cells were counted and suspended in X-VIVO 15 complete medium (5% hAB serum and cytokine mixture: 20 ng / ml hIL-2, 20 ng / ml hGM-CSF, 10 ng / ml hIL-4 and 10 ng / ml hTGF-b1) at a cell density of 3x10 6 cells / ml.

[0266] In the experiment, 3×10 6Each cell was seeded in the corresponding wells of a 12-well plate with a final volume of 1000 μl of X-VIVO complete medium containing a cytokine cocktail and 5 μg / ml AIM Bio molecules or corresponding controls.

[0267] On day 3, 1 ml of complete medium (containing cytokines) was added, and on day 6, a second pulse stimulation (after removal of the medium) was performed with 5 μg / ml of the recombinant polypeptide of the present invention or its surrogate (collectively referred to as "AIM Bio" molecules). On days 7, 10, and 12, 1 ml of complete medium (containing cytokines) was added.

[0268] Material:

[0269] X-VIVO 15 medium + 5% human AB serum

[0270] X-VIVO 15 complete medium: X-VIVO 15 medium + 2% human AB serum, supplemented with cytokine mixture: 10ng / ml TGF-b1, 10ng / ml IL-4, 20ng / ml IL-2, 20ng / ml GM-CSF

[0271] 6-well and 12-well plates

[0272] 2) ELISPOT

[0273] On day 13, ELISPOT plates were coated with anti-IL10 (clone 9D-7, diluted 1:500 in PBS, sterile filtered) and aIL10 (10G8-biotin), and on day 14, 200,000 cells were seeded per well on the ELISPOT plates in duplicate, including a negative control (cells plus PBS) and a positive control (e.g., LPS).

[0274] The PVDF membrane was activated with 50 μl / well EtOH (35% v / v) for 1 min, and then washed 5 times with 200 μl distilled sterile water. The plate was coated with 100 μl / well antibody solution at 4°C overnight. The next day, unbound coated antibody was removed, 5 washing steps were performed with 200 μl PBS, and 200 μl blocking buffer (X-VIVO 15 5% hAB serum) was added, and the plate was incubated at room temperature for 30 min-2 h.

[0275] Prepare DMSO (e.g. MOG157) containing the corresponding antigenic peptide or DMSO as a control, and add a final amount of 5 μg peptide / ml to a final volume of 100 μl / well. 150,000 cells are seeded per well in X-VIVO 15 medium containing 5% human AB serum. Carefully remove the blocking buffer (X VIVO 15 medium + 5% hAB serum), and use a medium containing PBS as a negative control, and add the stimulator (5 μg / ml per well total volume) to other wells and incubate overnight at 37°C.

[0276] Outside the laminar flow hood

[0277] Secondary antibody preparation: 1 μg / ml aIL-10-biotinylated antibody (1:1000 dilution) and horseradish peroxidase-conjugated streptavidin (0.5% BSA / PBS, 1:750 dilution) in 0.5% BSA / 1×PBS. The tetramethylbenzidine solution was filtered using a 0.45 μm filter and stored at 4°C until use.

[0278] Remove the cell supernatant and wash five times with 100 μl PBS. Finally, remove the excess buffer with paper.

[0279] 25 μl of diluted HRP-streptavidin (1:750) was added to each well, incubated for 1 h at room temperature in the dark, and then washed five times with sterile 1× PBS.

[0280] Add 100 μl of filtered TMB substrate to each well and let stand for 15-25 min until blue spots appear. Rinse the wells thoroughly with tap water to stop the reaction.

[0281] Remove the board's plastic drain and rinse the bottom and sides of the board with tap water and allow to dry.

[0282] Plate data were read using an ImmunoSpot S6 Ultra-V analyzer (Cellular Technology Limited), analyzed in Excel, and graphs / statistics were plotted in Graphad Prism.

[0283] Required: Capture antibody: anti-hIL10 (clone: ​​9D-7, Mabtech #3430-3-250; 1:500 dilution), anti-hIL10 biotinylated (Mabtech, #3430-6-250), 1×PBS (sterile), 35% EtOH (v / v); Blocking buffer: X-vivo 5% hAB serum (sterile) [blocking was performed in the same medium as the cell culture]; Dilution buffer: 0.5% BAS in PBS; Washing buffer: 1×PBS; Culture medium: for T cells, X-VIVO 15 culture medium (Lonza); Filter syringe: Millex GV, ELISPOT PVDF plate (#MSIP4510, Millipore), TMB substrate

[0284] Example 2 : The surrogate molecules of the recombinant polypeptide of the present invention induce Tregs that secrete IL10 in mice.

[0285] Wild-type black 6 mice were injected with 100 μg of a recombinant polypeptide (also called "AIMBio") having the following sequence,

[0286] Ova_KbG

[0287] SIINFEKLGCGASGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPK IVKWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAVSRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQSFRVDLRTLLGCYN QSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGCDYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDPPKTHVTHHPVFDYEAT LRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC(SEQ ID NO:46)

[0288] and

[0289] Gp34_KbG

[0290] AVYNFATMGCGASGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPK IVKWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAVSRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQSFRVDLRTLLGCYN QSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGCDYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDPPKTHVTHHPVFDYEAT LRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC(SEQ ID NO:47).

[0291] Inducing tolerance to OVA peptide or viral Gp34 peptide, respectively. Gp34 is a well-characterized T cell epitope derived from the glycoprotein of lymphocytic choriomeningitis virus (LCMV). Although this epitope was traditionally named Gp33, it was later discovered that H2-K b The epitope presented on H2-K d The epitope on the H2-K b The epitope was named Gp34, which is in line with the latest recommendations. However, the use of the nomenclature Gp33 and Gp34 in the literature remains unclear. The first 8 amino acids of SEQ ID NO:47 show the corresponding peptide sequence. Two weeks later, mice were sacrificed and spleen cells were restimulated with matched or mismatched peptides. IL-10 secreting cells were quantified by ELIspot. The results are shown in Figure 3 shown.

[0292] Example 3 : The recombinant polypeptide surrogate molecules of the present invention prevent CD8+ T cell-driven EAE in mice.

[0293] As described in (Na et al, Brain. 2008 Sep; 131(Pt 9): 2353-65.), theb CD8 recognizes ovalbumin epitope in the context of + Adoptive transfer of OT-I T cells into mice expressing ovalbumin in their oligodendrocytes resulted in experimental autoimmune encephalomyelitis that recapitulated many of the symptoms of MS and MOGAD. In this animal model, a single injection of 500 μg of a recombinant peptide surrogate molecule that induces tolerance to the targeted ovalbumin epitope (also called “AIMBio”) almost completely prevented EAE symptoms, whereas a surrogate molecule presenting a control peptide had no significant protective effect ( Figure 4 ). The sequence of the recombinant polypeptide replacement molecule is shown in Example 2.

[0294] In the same model, the inventors further demonstrated that the use of antigenic peptides presented in target tissues or cells can produce effective bystander immunosuppression. Here, each mouse was injected with 250 μg of a recombinant peptide replacement molecule (also called "AIMBio") ( Figure 5 ). The sequence of the recombinant polypeptide replacement molecule is as follows:

[0295] Mog44_DbG

[0296] FSRVVHLYRNGGCGASGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHP

[0297] SDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVK

[0298] WDRDMGGGGSGGGGSGGGGSGGGGSGPHSMRYFETAVSRPGLEEPRYISVGYVDNKEFV

[0299] RFDSDAENPRYEPRAPWMEQEGPEYWERETQKAKGQEQWFRVSLRNLLGCYNQSAGGSH

[0300] TLQQMSGCDLGSDWRLLRGYLQFAYEGRDYIALNEDLKTWTAADMAAQITRRKWEQSGA

[0301] AEHYKAYLEGECVEWLHRYLKNGNATLLRTDPPKTHVTHHPVFDYEATLRCWALGFYPAE

[0302] IILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLR

[0303] WSKEGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC(SEQ ID NO:48)

[0304] Mog37_DbG

[0305] VGWYRSPFSRGCGASGGGGSGGGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIE

[0306] VDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDR

[0307] DMGGGGSGGGGSGGGGSGGGGSGPHSMRYFETAVSRPGLEEPRYISVGYVDNKEFVRFDS

[0308] DAENPRYEPRAPWMEQEGPEYWERETQKAKGQEQWFRVSLRNLLGCYNQSAGGSHTLQQ

[0309] MSGCDLGSDWRLLRGYLQFAYEGRDYIALNEDLKTWTAADMAAQITRRKWEQSGAAEHY

[0310] KAYLEGECVEWLHRYLKNGNATLLRTDDPKTHVTHHPVFDYEATLRCWALGFYPAEIILTW

[0311] QRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWSK

[0312] EGDGGIMSVRESRSLSEDLGSPDRVRAVSHWSSC (SEQ ID NO: 49).

[0313] Example 4 : Some recombinant polypeptides of the present invention selectively prevent CD4 + T cell-driven EAE.

[0314] On day 0, 33 μg or 100 μg of the recombinant polypeptide of the replacement molecule of the present invention ("AIM Bio") was injected intraperitoneally, 100 μl of MOG35-55 peptide / CFA (complete Freund's adjuvant; final concentration of Mycobacterium tuberculosis H37RA and peptide was 1 mg / ml each) emulsion was injected subcutaneously into the left and right flanks, and 250 ng of pertussis toxin (in 200 μl PBS) was injected intraperitoneally. A second pertussis toxin injection was performed 3 days later. In this animal model, a single injection of AIM Bio replacement molecules that induce tolerance to the Mog epitope (Mog44_DbG) significantly alleviated EAE symptoms, while replacement molecules presenting a control peptide (Gp34) or a non-functional Mog peptide (Mog37) had no significant protective effect ( Figure 6 In this model, Mog44 AIM Bio also prevented inflammation and CD8 T cell infiltration in the spinal cord ( Figure 7 ). The sequence of the recombinant polypeptide replacement molecule is shown in Example 3.

[0315] In this model, Mog44 AIM Bio also completely prevented the formation of MOG-specific autoantibodies in serum as detected by ELISA ( Figure 8 and Fig.11 ). This strongly suggests that the recombinant polypeptides of the invention are effective therapeutic agents for MS and MOGAD, two diseases that are often characterized by antibody responses against MOG. Thus, the patient populations are defined by common autoimmune-related antigens.

[0316] Mog-reactive antibodies in the sera of mice treated with AIM Bio (33 or 100 μg) were detected by a standard ELISA protocol with 3 washes between each step. Briefly, the ELISA plate was coated with 10 μg / ml Mog35-55 peptide, blocked with PBS 1% BSA, and then mouse sera diluted 1:25 in PBS 1% BSA were added and allowed to stand for 1 h. Anti-mouse IgG-HRP or anti-mouse heavy and light chain-HRP antibodies were used for detection at a dilution of 1:5000.

[0317] Example 5 :Human recombinant polypeptide candidates for MS and MOGAD of the present invention.

[0318] The recombinant polypeptides of the present invention are newly developed protein complexes derived from the pregnancy-related immunosuppressive MHC molecule HLA-G. HLA-G may enable the embryo to influence the maternal immune system, making it tolerant to embryonic antigens but further antagonizing pathogen antigens. The recombinant polypeptides containing various peptides of the present invention can selectively eliminate peptide-specific cytotoxic effector T cells and induce peptide-specific regulatory T cells in vitro.

[0319] Fig. 9A list of human MS and MOGAD recombinant polypeptide candidates is shown.

[0320] The inventors' results show that a single-chain protein containing myelin peptide antigen and HLA-Gα3 domain can induce tolerant T cells in healthy donors. Fig.10 ) upregulates CD8 Treg by at least 30% in 75% of healthy blood donors.

[0321] Example 6 : Further proof of concept of the stability and effect of the recombinant polypeptide of the present invention.

[0322] In addition, the inventors set out to obtain and test recombinant polypeptides having the general structure of the recombinant polypeptides of the present invention but containing various different peptide antigens in order to obtain further proof of concept and prove that the recombinant polypeptides of the present invention and their replacement molecules are stable and effective. Fig.12 and Fig.13 As shown in Figure 2, the tested recombinant polypeptides remained stable during freeze-thaw and storage and were thermostable. In addition, they induced Tregs ( Fig.14 ) and inhibited T cell lysis in a dose-dependent manner ( Fig.15 ). The effects of recombinant peptides on the serum cytokine profile of EAE-ODC Ova mice, such as Fig.16 As shown. IL-10 and possibly IL-4 were induced, both known immunosuppressive cytokines that downregulate immune responses in inflammatory settings. This required the HLA-G α3 domain plus the cognate peptide. Induction of IL-2 appeared to occur upon presentation of the cognate peptide to the cells independent of the α3 domain. IL-2 is required for T cell activation and survival.

[0323] Example 7 The MOG tolerance-inducing recombinant polypeptide of the present invention can prevent spinal cord cell apoptosis (cleaved caspase3), CD3 + Immune cell infiltration and myelin damage. Mouse models such as Figure 6 shown.

[0324] Immunofluorescence analysis of the spinal cord in the MOG-induced EAE model.

[0325] Material:

[0326] Primary Antibody

[0327] α-CD3i clone CD3-12 (1:100); rat monoclonal (rat anti-human, cross-reactive with mouse, Bio-rad); α-MBP (1:300, rabbit monoclonal, MBL); α-cleaved caspase3 (1:400, rabbit monoclonal, CellSignaling)

[0328] DAPI (1:500, Sigma #D8417)

[0329] Secondary Antibodies

[0330] α-rabbit-Cy3 (red, 1:300, Dianova #111-165-144); α-rat-AF488 (green, 1:300, Invitrogen) or α-rabbit-Cy3 (red, 1:300, Dianova #112-165-167)

[0331] step

[0332] The frozen sections were warmed at room temperature for 5 min, the stained areas were marked with a Pap-Pen, fixed in acetone, and placed at -20°C for 10 min.

[0333] Washing: 1×PBS wash 3 times

[0334] Blocking 1h: 5% BSA + 0.2% Triton-X100 + 5% NGS in 1×PBS

[0335] Primary antibody: 1% BSA + 1% NGS + 0.2% Triton-X100; 4°C, overnight

[0336] Washing: 1×PBS wash 3 times

[0337] Secondary antibody: 1% BSA + 1% NGS + 0.2% Triton-X100; RT, 1h

[0338] Washing: 1×PBS wash 3 times

[0339] DAPI: 1:300 in 1× PBS, 10 min, RT

[0340] Washing: 1×PBS wash twice

[0341] Mounting with Aquapolymount

[0342] Detailed results:

[0343] Fig.17 A, B: Caspase 3 activation (apoptosis) can be prevented in MOG-induced EAE spinal cord. A: images; B: quantification.

[0344] Fig.17 C, D: MOG-induced EAE spinal cord white matter damage can be blocked. C: Image; D: Quantification.

[0345] Fig.17 E, F: CD3 infiltration into the spinal cord can be prevented in MOG-induced EAE. E: images; F: quantification.

[0346] Example 8 :IL10 spots increased after MOG157_A2G treatment.

[0347] Fig.18 The results showed an increase in IL10 spots after treatment with MOG157_A2G, indicating that tolerogenic Tregs had been induced. Fig.10 Another description of .

[0348] Industrial Applicability

[0349] The pharmaceutical compositions, polypeptides, nucleic acids, cells and products used in the present invention have industrial application value. For example, they can be used to manufacture medicines or as medicines.

Claims

1. A recombinant polypeptide capable of presenting a peptide antigen, the recombinant polypeptide comprising, in order from N-terminus to C-terminus: i) a peptide antigen presented by the recombinant polypeptide, wherein the peptide antigen is a peptide of human myelin-oligodendrocyte glycoprotein (MOG), human myelin basic protein (MBP), human myelin associated glycoprotein (MAG), or human myelin proteolipid protein (PLP1); ii) optionally, a linker sequence; iii) optionally, a human polypeptide domain sequence, the human polypeptide domain sequence comprising a human β2 microglobulin sequence, or an amino acid sequence that is at least 90% identical to the human β2 microglobulin amino acid sequence shown in SEQ ID NO: 5; iv) optionally, a linker sequence; v) optionally, an α1 domain of an MHC molecule; vi) optionally, an α2 domain of an MHC molecule; vii) an α3 domain of an MHC class Ib molecule or a derivative of the α3 domain of an MHC class Ib molecule, said derivative being capable of binding to ILT2 or ILT4; viii) optionally, a protease cleavage site; ix) optionally, a spacer sequence; and x) Optionally, an affinity tag.

2. The recombinant polypeptide according to claim 1, wherein the length of the peptide antigen according to i) is 7 to 11 amino acids, preferably 8 to 10 amino acids.

3. The recombinant polypeptide according to claim 1 or 2, wherein the peptide antigen according to i) consists of an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 32 and SEQ ID NO:

33.

4. The recombinant polypeptide according to claim 1, wherein the peptide antigen according to i) consists of an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 28 and SEQ ID NO:

30.

5. The recombinant polypeptide according to any one of the preceding claims, wherein the peptide antigen according to i) is a peptide of human myelin-oligodendrocyte glycoprotein (MOG). 6 . The recombinant polypeptide according to any one of claims 1 to 2 and 4 to 5 , wherein the peptide antigen consists of the amino acid sequence of SEQ ID NO:

2.

7. The recombinant polypeptide according to any one of the preceding claims, wherein the α1 domain according to (v) and the α2 domain according to (vi) are from a human MHC class Ia molecule or from a human MHC class Ib molecule.

8. The recombinant polypeptide according to claim 7, wherein the α1 domain according to (v) and the α2 domain according to (vi) are derived from human MHC I class Ia molecules. 9 . The recombinant polypeptide according to claim 8 , wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human HLA-A2 molecules.

10. The recombinant polypeptide according to claim 7, wherein the α1 domain according to (v) and the α2 domain according to (vi) are from human MHC class Ib molecules.

11. The recombinant polypeptide according to any one of the preceding claims, wherein the α3 domain of the MHC class Ib molecule according to (vii) is the α3 domain of human HLA-E, human HLA-F or human HLA-G.

12. The recombinant polypeptide according to any one of the preceding claims, wherein the α3 domain of the MHC class Ib molecule according to (vii) is the α3 domain of human HLA-G.

13. A recombinant polypeptide according to any of the preceding claims, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:21, or has at least 80% amino acid sequence identity, preferably at least 90% amino acid sequence identity, with the α3 domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:

21.

14. The recombinant polypeptide according to claim 13, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21, or has at least 92% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

15. The recombinant polypeptide according to claim 13, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21, or has at least 94% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

16. The recombinant polypeptide of claim 13, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21, or has at least 96% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

17. The recombinant polypeptide of claim 13, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21, or has at least 98% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

18. The recombinant polypeptide of claim 13, wherein the α3 domain or derivative according to (vii) is identical to the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 21, or has at least 99% amino acid sequence identity with the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

19. The recombinant polypeptide according to claim 13, wherein the α3 domain according to (vii) is the same as the α3 domain having the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:

21.

20. A recombinant polypeptide according to any one of the preceding claims, wherein the linker sequence according to (ii) and / or the linker sequence according to (iv) comprises the amino acid sequence (GGGGS)n, wherein n is an integer equal to or greater than 1.

21. The recombinant polypeptide according to claim 20, wherein the linker sequence according to (ii) comprises the amino acid sequence (GGGGS)n, wherein n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and is preferably selected from the group consisting of 2, 3, 4 and 5.

22. A recombinant polypeptide according to claim 20 or 21, wherein the linker sequence according to (iv) comprises the amino acid sequence (GGGGS)n, wherein n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and is preferably selected from the group consisting of 2, 3, 4 and 5.

23. A recombinant polypeptide according to any one of the preceding claims, wherein the sequence of the human polypeptide domain according to (iii) is at least 95% identical to the amino acid sequence of SEQ ID NO:5, preferably at least 98% identical to the amino acid sequence of SEQ ID NO:5, and more preferably identical to the amino acid sequence of SEQ ID NO:

5.

24. The recombinant polypeptide according to any one of the preceding claims, wherein the polypeptide is a dimer or a multimer.

25. The recombinant polypeptide according to any one of the preceding claims, wherein the polypeptide comprises or consists of all components i) to vii).

26. The recombinant polypeptide according to any one of the preceding claims, wherein the polypeptide does not comprise components viii) to x).

27. The recombinant polypeptide according to any one of claims 1 to 25, wherein the polypeptide comprises or consists of all components i) to x).

28. The recombinant polypeptide according to any one of the preceding claims, further comprising an N-terminal secretion signal peptide sequence.

29. The recombinant polypeptide according to any one of claims 1 to 27, wherein the recombinant polypeptide consists of the following amino acid sequence, which consists of the following ((a) and (b)) in order from N-terminus to C-terminus: (a) a peptide antigen selected from the group consisting of the amino acid sequences of SEQ ID NO:2, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33; and (b) The amino acid sequence of SEQ ID NO:

16.

30. The recombinant polypeptide according to any one of the preceding claims, wherein the recombinant polypeptide is soluble.

31. A nucleic acid encoding one or more polypeptides according to any one of the preceding claims.

32. The nucleic acid of claim 31, wherein the nucleic acid is a vector.

33. A pharmaceutical composition comprising at least one nucleic acid according to claim 31 or 32.

34. A pharmaceutical composition or kit comprising at least one recombinant polypeptide according to any one of claims 1 to 30.

35. The pharmaceutical composition or kit according to claim 34, wherein the pharmaceutical composition or kit comprises at least two different recombinant polypeptides according to any one of claims 1 to 30, wherein each different polypeptide comprises a different peptide antigen as defined in any one of claims 1 to 6.

36. A pharmaceutical composition or kit according to any one of claims 33 to 35 for use in treating multiple sclerosis (MS), MOG antibody disease or MOG antibody-positive neuromyelitis optica in a human patient.

37. A pharmaceutical composition or kit for use according to claim 36, wherein the treatment is the treatment of multiple sclerosis (MS).

38. The pharmaceutical composition or kit for use according to claim 36, wherein the treatment is treatment of a MOG antibody disease.

39. The pharmaceutical composition or kit for use according to claim 36, wherein the treatment is the treatment of MOG antibody-positive neuromyelitis optica.

40. A pharmaceutical composition or kit for use according to any one of claims 36 to 39, wherein the treatment is treatment by immunotherapy.

41. The pharmaceutical composition or kit for use according to any one of claims 36 to 40, wherein the treatment is performed by inducing immune tolerance against human myelin-oligodendrocyte glycoprotein.

42. A pharmaceutical composition or kit for use according to any one of claims 36 to 41, wherein the treatment is for reducing the level of autoantibodies against human myelin-oligodendrocyte glycoprotein in plasma or cerebrospinal fluid.

43. The pharmaceutical composition or kit for use according to any one of claims 36 to 42, wherein the human patient is a patient having anti-myelin-oligodendrocyte glycoprotein autoantibodies in plasma or cerebrospinal fluid before the start of treatment.

44. The pharmaceutical composition or kit for use according to any one of claims 36 to 43, wherein the treatment is performed by inducing myelin-specific regulatory T cells.

45. A recombinant host cell comprising the nucleic acid or vector according to claim 31 or 32, and expressing the recombinant polypeptide according to any one of claims 1 to 30.

46. ​​A method for obtaining a pharmaceutical composition comprising a polypeptide according to any one of claims 1 to 30, the method comprising the following steps: (a) culturing the recombinant host cell of claim 45 under conditions that allow expression of the recombinant polypeptide from the nucleic acid molecule, (b) recovering the recombinant polypeptide, (c) purifying the recombinant polypeptide, and (d) formulating the recombinant polypeptide into a pharmaceutical composition.